Mar 29, 2026

Subject: 💊 Discount Drug Program Changes Stir Debate

Hi,

Big changes are coming to the federal 340B discounted drug program, used by safety net hospitals and clinics to stretch resources. Major drugmakers like Eli Lilly and Novo Nordisk are now imposing data-reporting requirements, aimed at preventing providers from allegedly “gaming” the system to boost profits.

Why it matters: The 340B program covers over $81 billion annually on drug purchases, and these savings help providers support essential community services. Provider groups warn the new rules will be costly and could force cuts in services or even closures.

Key points:

– Eli Lilly requires providers to submit claims data or pay full price starting February; Novo Nordisk follows with similar rules.

– Providers and advocacy groups argue these demands are punitive and expensive.

– The Trump administration is considering changes, including shifting to a rebate model and surveying hospital drug costs that may impact Medicare payments.

– Spending on 340B drugs has increased sixfold since 2010, fueling concerns about misuse.

– Some states legislate to protect or restrict aspects of the program amid legal disputes.

Impact: Providers dependent on 340B discounts underscore the program’s role in funding vital but low-revenue services, like obstetrics and free vaccines. Proposed cuts and restrictions risk harming patient access and public health safety nets.

Stakeholders continue to debate reforms at congressional and state levels, but no clear path has emerged yet.

Best,

[Your Name]

Stay Well!